These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28167552)

  • 1. Pharmacokinetics of Benznidazole in Healthy Volunteers and Implications in Future Clinical Trials.
    Molina I; Salvador F; Sánchez-Montalvá A; Artaza MA; Moreno R; Perin L; Esquisabel A; Pinto L; Pedraz JL
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.
    de Jesus SM; Pinto L; Moreira FL; Nardotto GHB; Cristofoletti R; Perin L; Fonseca KDS; Barbêdo P; Bandeira LC; Vieira PMA; Carneiro CM
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review and Meta-analysis of the Pharmacokinetics of Benznidazole in the Treatment of Chagas Disease.
    Wiens MO; Kanters S; Mills E; Peregrina Lucano AA; Gold S; Ayers D; Ferrero L; Krolewiecki A
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7035-7042. PubMed ID: 27550362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease.
    Pinazo MJ; Guerrero L; Posada E; Rodríguez E; Soy D; Gascon J
    Antimicrob Agents Chemother; 2013 Jan; 57(1):390-5. PubMed ID: 23114763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults.
    Altcheh J; Moscatelli G; Mastrantonio G; Moroni S; Giglio N; Marson ME; Ballering G; Bisio M; Koren G; García-Bournissen F
    PLoS Negl Trop Dis; 2014 May; 8(5):e2907. PubMed ID: 24853169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice.
    Perin L; Moreira da Silva R; Fonseca KD; Cardoso JM; Mathias FA; Reis LE; Molina I; Correa-Oliveira R; Vieira PM; Carneiro CM
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of benznidazole in adult patients with Chagas disease.
    Soy D; Aldasoro E; Guerrero L; Posada E; Serret N; Mejía T; Urbina JA; Gascón J
    Antimicrob Agents Chemother; 2015; 59(6):3342-9. PubMed ID: 25824212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacokinetics of benznidazole-loaded interpolyelectrolyte complex-based delivery systems.
    García MC; Guzman ML; Himelfarb MA; Litterio NJ; Olivera ME; Jimenez-Kairuz A
    Eur J Pharm Sci; 2018 Sep; 122():281-291. PubMed ID: 30018011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole.
    Fernández ML; Marson ME; Ramirez JC; Mastrantonio G; Schijman AG; Altcheh J; Riarte AR; Bournissen FG
    Mem Inst Oswaldo Cruz; 2016 Mar; 111(3):218-21. PubMed ID: 26982179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method.
    Moreira da Silva R; Oliveira LT; Silva Barcellos NM; de Souza J; de Lana M
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3344-8. PubMed ID: 22450981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.
    Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.
    Xu M; Ni Y; Zhou Y; He X; Li H; Chen H; Li W
    Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high-performance liquid chromatographic method for benznidazole quantitation in plasma of patients with Chagas disease.
    Guerrero L; Pinazo MJ; Posada E; Gascón J; Ribas J; Soy D
    Clin Chem Lab Med; 2011 Jan; 49(1):77-82. PubMed ID: 21083440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial.
    Molina-Morant D; Fernández ML; Bosch-Nicolau P; Sulleiro E; Bangher M; Salvador F; Sanchez-Montalva A; Ribeiro ALP; de Paula AMB; Eloi S; Correa-Oliveira R; Villar JC; Sosa-Estani S; Molina I
    Trials; 2020 Apr; 21(1):328. PubMed ID: 32293523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
    Tan QY; Li HD; Zhu RH; Zhang QZ; Zhang J; Peng WX
    Am J Cardiovasc Drugs; 2013 Feb; 13(1):17-25. PubMed ID: 23355361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
    Torrico F; Gascon J; Ortiz L; Alonso-Vega C; Pinazo MJ; Schijman A; Almeida IC; Alves F; Strub-Wourgaft N; Ribeiro I;
    Lancet Infect Dis; 2018 Apr; 18(4):419-430. PubMed ID: 29352704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.
    Wenzler E; Ellis-Grosse EJ; Rodvold KA
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid and sensitive ultra-high-pressure liquid chromatography method for quantification of antichagasic benznidazole in plasma: application in a preclinical pharmacokinetic study.
    Davanço MG; de Campos ML; Peccinini RG
    Biomed Chromatogr; 2015 Jul; 29(7):1008-15. PubMed ID: 25424984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres.
    Crespillo-Andújar C; López-Vélez R; Trigo E; Norman F; Díaz-Menéndez M; Monge-Maillo B; Arsuaga M; Pérez-Molina JA
    Clin Microbiol Infect; 2020 Mar; 26(3):384.e1-384.e4. PubMed ID: 31740423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benznidazole Extended-Release Tablets for Improved Treatment of Chagas Disease: Preclinical Pharmacokinetic Study.
    Davanço MG; Campos ML; Rosa TA; Padilha EC; Alzate AH; Rolim LA; Rolim-Neto PJ; Peccinini RG
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2492-8. PubMed ID: 26883698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.